Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome
Polycystic Ovary
About this trial
This is an interventional treatment trial for Polycystic Ovary focused on measuring polycystic ovary, liraglutide
Eligibility Criteria
Inclusion Criteria: aged between 20 and 45 years PCO Exclusion Criteria: congenital adrenal hyperplasia poorly controlled thyroid disease Taking antidiabetic drugs which can affect insulin resistance chronic kidney disease and history of recurrent urinary tract infections liver dysfunction documented use of oral hormonal contraceptives and hormone-releasing implants
Sites / Locations
- Beni-suef university Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
No Intervention
liraglutide
metformin
control
Saxenda® starting dose is 0.6 mg per day for 1 week.1. Patients increase the dose by 0.6 mg each week until the full maintenance dose of 3 mg is reached
the patient is given Glucophage 1000 mg tab once daily after lunch for 1month
not given any drug